Allergy Therapeutics has released an interim trading update for the six months to 31 December 2016 with 1H reported revenues ‘ahead of expectations’ and expected to be £40.4m (2015: £29.0m) which represents growth of 17.9% at constant currency, or +39.3% on a reported basis. We upgrade forecasts – mainly focusing on the revenue line for FY17E and FY18E (+5.5% in each year) at this stage – but it is clear that commercial momentum is strong. A regulatory upda
